Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib

Endocrine. 2015 Aug;49(3):854-8. doi: 10.1007/s12020-014-0448-y. Epub 2014 Oct 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Iodine Radioisotopes / therapeutic use
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Pyrroles / therapeutic use*
  • Sorafenib
  • Sunitinib
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / radiotherapy
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Indoles
  • Iodine Radioisotopes
  • Phenylurea Compounds
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib